<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164765">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01850797</url>
  </required_header>
  <id_info>
    <org_study_id>S-556/2011</org_study_id>
    <nct_id>NCT01850797</nct_id>
  </id_info>
  <brief_title>Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)</brief_title>
  <acronym>RASUNOA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <authority>Germany: ethics committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry of acute stroke under new oral anticoagulants (RASUNOA) is a German
      multicenter, prospective, observational registry performed at about 50 study centers
      covering about 50.000 acute ischemic strokes and 6000 acute intracranial hemorrhages per
      year. Study enrollment will be consecutive. The RASUNOA registry study center is the
      University Medical Center of the Principal Investigator (Heidelberg, Germany). The registry
      will focus on treatment decisions and concepts in patients being under treatment with a new
      oral anticoagulant and suffering from acute ischemic or hemorrhagic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of the study is to collect information from a large, prospectively
      enrolling multicentre stroke database regarding the optimal management of ischemic and
      hemorrhagic stroke during anticoagulation with nOAC. Specifically, we aim to obtain critical
      information regarding the epidemiology, natural history, laboratory and neuroradiological
      aspects, clinical consequences, and the effects of treatment (i.e.
      thrombolysis/interventional recanalisation in ischemic stroke and hemostatic therapy in ICH,
      respectively) in stroke during nOAC. The Registry is not limited to a specific new OAC but
      intends to examine stroke during use of any of the approved nOAC. The study is not designed
      to perform comparisons among the different nOAC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Rate of hematoma expansion (ICH)</measure>
    <time_frame>48h after ICH</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of hematoma enlargement in patients with ICH between initial imaging and follow-up imaging (CT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic intracerebral haemorrhage after thrombolysis</measure>
    <time_frame>24 h</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In patients with ischemic stroke while under treatment with any of the new OAC who receive thrombolysis we will measure any hemorrhagic transformation on routine follow-up CT imaging (usually within 24h after thrombolysis)</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Intracranial Hemorrhage</condition>
  <arm_group>
    <arm_group_label>NOAC</arm_group_label>
    <description>Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients suffering from acute ischemic stroke or intracranial hemorrhage while being anti
        coagulated. Only patients taking new oral anticoagulants will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;= 18 years

          -  informed consent

          -  acute stroke or intracranial bleeding

          -  therapy with a new oral anticoagulant (Dabigatran速, Rivaroxaban速, Apixaban速,
             Edoxaban速)

        Exclusion Criteria:

          -  missing informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Veltkamp, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland Veltkamp, Prof.</last_name>
    <phone>0049 6221 56</phone>
    <phone_ext>7504</phone_ext>
    <email>roland.veltkamp@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jan C Purrucker, MD</last_name>
    <phone>0049 6221 56</phone>
    <phone_ext>37718</phone_ext>
    <email>jan.purrucker@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perdita Beck, SN</last_name>
      <phone>0049 6221 56</phone>
      <phone_ext>38121</phone_ext>
      <email>perdita.beck@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jan C Purrucker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timolaos Rizos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-heidelberg.de/Schlaganfall-Studien.707.0.html</url>
    <description>RASUNOA - Center Homepage</description>
  </link>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 7, 2013</lastchanged_date>
  <firstreceived_date>May 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Heidelberg</investigator_affiliation>
    <investigator_full_name>Prof. Roland Veltkamp</investigator_full_name>
    <investigator_title>Senior Physician, Department of Neurology, University Hospital Heidelberg</investigator_title>
  </responsible_party>
  <keyword>oral anticoagulants</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>blood thinner</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
